novo nordisk's semaglutide failed to slow alzheimer's disease progression Popular obesity drug fails in hotly anticipated trials | Science Novo Nordisk's semaglutide fails to
Description
A new study is raising concerns about GLP-1 weight loss drugs and eating disorders

Some people see rapid results, while others may progress slowly
The high levels of patient satisfaction speak to their effectiveness, as more clients share their success stories with others seeking similar transformations

No monitoring

On the hardest days, a protein shake plus yogurt plus one small real-food meal can keep you on track

Once your prescription is approved, medication ships directly to your doorstep
